June 30 (Reuters) - AN2 Therapeutics Inc ANTX.O:
AN2 THERAPEUTICS REPORTS KEY INSIGHTS FROM 200-PATIENT OBSERVATIONAL STUDY IN ACUTE MELIOIDOSIS, LAYING GROUNDWORK FOR PHASE 2 PROOF-OF-CONCEPT TRIAL OF EPETRABOROLE
AN2 THERAPEUTICS INC - TO INITIATE PHASE 2 TRIAL LATER THIS YEAR
Source text: ID:nBw6QVtwpa
Further company coverage: ANTX.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.